Phase 1B Study of RiVax, a Vaccine to Prevent the Toxic Effects of Ricin

Completed · Phase 1

Conditions studied: Healthy

In brief

Dose escalation study: 3 dose groups. 5 patients in each dose group, then 15 more patients in "best" group. 3 vaccinations in volunteers, at 0 6 and 16 weeks.

Key facts

Study ID

NCT00812071

Run by

University of Texas Southwestern Medical Center

People needed

30

Starts

2008-03-01

Expected to finish

2012-05-01

Last updated by the study team

2013-08-20

Who can join

Age: 18 and older, up to 31. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• healthy volunteers aged 18-31, m or f

You may not qualify if…

• immunodeficiency
• pregnant
• chronic disease
• parental IgG
• abnormal labs
• drug use
• hiv
• hep c
• hep b

Where it is running

• Hampton Roads Center For Clinical Research — Chesapeake, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.